DRUG CONCENTRATION RESPONSE RELATIONSHIPS IN NORMAL VOLUNTEERS AFTER ORAL-ADMINISTRATION OF LOSARTAN, AN ANGIOTENSIN-II RECEPTOR ANTAGONIST

被引:199
作者
MUNAFO, A
CHRISTEN, Y
NUSSBERGER, J
SHUM, LY
BORLAND, RM
LEE, RJ
WAEBER, B
BIOLLAZ, J
BRUNNER, HR
机构
[1] CHU VAUDOIS,DIV HYPERTENS,CH-1011 LAUSANNE,SWITZERLAND
[2] CHU VAUDOIS,DEPT MED,DIV CLIN PHARMACOL,CH-1011 LAUSANNE,SWITZERLAND
[3] DUPONT MERCK PHARMACEUT CO,CLIN RES DRUG METAB & PHARMACOKINET,WILMINGTON,DE
关键词
D O I
10.1038/clpt.1992.56
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to investigate the relationships between plasma concentrations of losartan, an orally active angiotensin II inhibitor, its active metabolite EXP3174, and angiotensin II blockade. Six healthy subjects received single oral doses of 40, 80, or 120 mg losartan and placebo at 1-week intervals in a crossover study. Angiotensin II blockade was assessed by the blood pressure response to exogenous angiotensin II before and after losartan administration. EXP3174 reached higher plasma concentrations and was eliminated more slowly than its parent compound; its levels paralleled the profile of angiotensin II blockade closer than losartan. Inhibition of the pressure response was dose dependent. The Hill-shaped relationship between response and EXP3174 concentration (or time-integrated variables) approached a plateau with 80 mg. The dose-dependent increase in plasma renin and angiotensin II exhibited a considerable individual scatter. We conclude that losartan produces a dose-dependent, effective angiotensin II blockade that is largely determined by the active metabolite EXP3174.
引用
收藏
页码:513 / 521
页数:9
相关论文
共 25 条
  • [1] BRUNNER HR, 1990, J HYPERTENS, V8, pS149
  • [2] NOMENCLATURE FOR ANGIOTENSIN RECEPTORS - A REPORT OF THE NOMENCLATURE-COMMITTEE OF THE COUNCIL-FOR-HIGH-BLOOD-PRESSURE-RESEARCH
    BUMPUS, FM
    CATT, KJ
    CHIU, AT
    DEGASPARO, M
    GOODFRIEND, T
    HUSAIN, A
    PEACH, MJ
    TAYLOR, DG
    TIMMERMANS, PBMWM
    [J]. HYPERTENSION, 1991, 17 (05) : 720 - 721
  • [3] CHIU AT, 1990, J PHARMACOL EXP THER, V252, P711
  • [4] INVITRO PHARMACOLOGY OF DUP 753
    CHIU, AT
    MCCALL, DE
    PRICE, WA
    WONG, PC
    CARINI, DJ
    DUNCIA, JV
    WEXLER, RR
    YOO, SE
    JOHNSON, AL
    TIMMERMANS, PBMWM
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1991, 4 (04) : S282 - S287
  • [5] CHRIST D, 1990, 3RD N AM ISSX M SAN, P34
  • [6] ORAL-ADMINISTRATION OF DUP-753, A SPECIFIC ANGIOTENSIN-II RECEPTOR ANTAGONIST, TO NORMAL-MALE VOLUNTEERS - INHIBITION OF PRESSOR-RESPONSE TO EXOGENOUS ANGIOTENSIN-I AND ANGIOTENSIN-II
    CHRISTEN, Y
    WAEBER, B
    NUSSBERGER, J
    PORCHET, M
    BORLAND, RM
    LEE, RJ
    MAGGON, K
    SHUM, L
    TIMMERMANS, PBMWM
    BRUNNER, HR
    [J]. CIRCULATION, 1991, 83 (04) : 1333 - 1342
  • [7] DOSE-RESPONSE RELATIONSHIPS FOLLOWING ORAL-ADMINISTRATION OF DUP 753 TO NORMAL HUMANS
    CHRISTEN, Y
    WAEBER, B
    NUSSBERGER, J
    LEE, RJ
    TIMMERMANS, PBMWM
    BRUNNER, HR
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1991, 4 (04) : S350 - S353
  • [8] Gibaldi M., 1982, PHARMACOKINETICS, P221
  • [9] UNDERSTANDING THE DOSE-EFFECT RELATIONSHIP - CLINICAL-APPLICATION OF PHARMACOKINETIC-PHARMACODYNAMIC MODELS
    HOLFORD, NHG
    SHEINER, LB
    [J]. CLINICAL PHARMACOKINETICS, 1981, 6 (06) : 429 - 453
  • [10] HOUSTON JB, 1986, PHARMACOKINETICS THE, P131